Table 3.
Postoperative factors affecting longterm survival in patients submitted to resection for hepatocellular carcinoma who did (Group A) and did not (Group B) survive for ≥10 years after resection (n = 176)
| Group A | Group B | ||
|---|---|---|---|
| Factors | (n = 28, 15.9%) | (n = 148, 84.1%) | P-value |
| Recurrence, n (%) | 18 (64.3%) | 94 (63.5%) | 0.938 |
| Intrahepatic/intra-extra/extrahepatic, n (Missing data: 1, 0.5%) | 16/2/0 | 54/26/13 | 0.049 |
| Single recurrence, n | 13/18 | 30/94 | 0.009 |
| (Missing data: 16, 14.3%) | |||
| Recurrence at < 2 years, n | 6/18 | 80/94 | <0.001 |
| BCLC class A/B/C/D, n | 12/0/2/0 | 27/9/39/4 | 0.006 |
| (Missing data: 19, 17.0%) | |||
| AFP at recurrence, ng/ml, mean ± SD | 7340 ± 26 219 | 4723 ± 21 964 | 0.702 |
| (Missing data: 28, 25.0%) | |||
| AFP >400 ng/ml, n (%) | 2 (15.4%) | 15 (21.1%) | 1.000 |
| Type of treatment after recurrence, n (%) | 18 (64.3%) | 94 (63.5%) | 0.010 |
| (Missing data: 11, 9.8%) | |||
| Re-resection | 5/18 | 8/94 | |
| Transplant | 8/18 | 14/94 | |
| Radiofrequency ablation | 3/18 | 16/94 | |
| Transarterial chemoembolization | 1/18 | 19/94 | |
| Other (chemotherapy and/or radiation) | 1/18 | 16/94 | |
| Supportive care | – | 10/94 |
BCLC, Barcelona Clinic Liver Cancer; AFP, alpha-fetoprotein; SD, standard deviation.